MIRM Q2 2025 Earnings — Mirum Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MIRMMirum Pharmaceuticals, Inc.

$5B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$128M+64.1% YoY

Gross Profit

$104M81.7% margin

Operating Income

-$5M-3.9% margin

Net Income

-$6M-4.6% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+14.5%

Cash Flow

Operating Cash Flow

$12M

Free Cash Flow

$12M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$726M

Total Liabilities

$471M

Stockholders' Equity

$255M

Cash & Equivalents

$228M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$128M	$78M	+64.1%
Gross Profit	$104M	$58M	+81.0%
Operating Income	-$5M	-$24M	+79.4%
Net Income	-$6M	-$25M	+76.2%

Revenue Segments

Product

$128M100%

Geographic Segments

UNITED STATES

$96M75%

Rest Of World

$32M25%